These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 15955857)
1. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Grazioli L; Morana G; Kirchin MA; Schneider G Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857 [TBL] [Abstract][Full Text] [Related]
2. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959 [TBL] [Abstract][Full Text] [Related]
4. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging. Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728 [TBL] [Abstract][Full Text] [Related]
6. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891 [TBL] [Abstract][Full Text] [Related]
8. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging. Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278 [TBL] [Abstract][Full Text] [Related]
15. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media]. Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451 [TBL] [Abstract][Full Text] [Related]
16. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691 [TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527 [TBL] [Abstract][Full Text] [Related]
18. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial). Martincich L; Faivre-Pierret M; Zechmann CM; Corcione S; van den Bosch HC; Peng WJ; Petrillo A; Siegmann KC; Heverhagen JT; Panizza P; Gehl HB; Diekmann F; Pediconi F; Ma L; Gilbert FJ; Sardanelli F; Belli P; Salvatore M; Kreitner KF; Weiss CM; Zuiani C Radiology; 2011 Feb; 258(2):396-408. PubMed ID: 21163915 [TBL] [Abstract][Full Text] [Related]
19. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis. Kim YK; Lee YH; Kwak HS; Kim CS; Han YM Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]